THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of December 18, 2017, by and among Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), the Key Holders (as defined below), each Holder (as defined below) listed on Schedule I hereto (each Key Holder and Holder, a “Stockholder” and collectively, the “Stockholders”) and each stockholder of the Company that becomes a party to this Agreement in accordance with Section 6.9 hereof (each, an “Additional Stockholder”). Capitalized terms used in this Agreement but not otherwise defined have the meanings set forth in Sections 1.1 and 1.2.
Confidential Treatment Requested Centrexion Therapeutics Corporation PATENT ASSIGNMENT AND LICENSING AGREEMENT dated NOVEMBER 11, 2015 by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH hereinafter “BII” and CENTREXION THERAPEUTICS CORPORATION...Patent Assignment and Licensing Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations
Boehringer Ingelheim International GmbH (“BII”), a German limited liability company, with offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany; and
CENTREXION THERAPEUTICS CORPORATION WARRANT TO PURCHASE SHARESWarrant Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • New York
This Warrant is issued to Mr. Zhang Xuefeng by Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), as of December 30, 2016 (the “Effective Date”), in connection with the holder’s provision of consulting services to the Company pursuant to the consulting agreement, dated as of December 30, 2016 (the “Consulting Agreement.”)
Confidential Treatment Requested Centrexion Therapeutics Corporation AMENDMENT #1 TO PATENT ASSIGNMENT AND LICENSING AGREEMENTPatent Assignment and Licensing Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations
This Amendment No. 1 (“Amendment No. 1”) to the Patent Assignment and Licensing Agreement by and between Boehringer Ingelheim International GmbH (“BII”) and Centrexion Therapeutics Corporation (“CENTREXION”), dated November 11, 2015, (the “Agreement”) is entered into effective as of January 29, 2018.
LICENSE AGREEMENTLicense Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is entered into as of August 28, 2001 (the “Effective Date”) among JAMES N. CAMPBELL, M.D., RICHARD A. MEYER, M.S. and MARCO PAPPAGALLO, M.D. (collectively hereafter, the “Inventors”), and ALGORX PHARMACEUTICALS, INC., a Delaware corporation (“AlgoRx”).
